AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 17, 2021

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) announced it will report financial results for the fiscal quarter ending March 31, 2021, on May 17, 2021. A conference call will follow at 4:30 PM ET for management to review the results and provide updates. AGTC focuses on gene therapies for rare retinal diseases and is currently conducting clinical trials for X-linked retinitis pigmentosa and achromatopsia. The call will be accessible via phone and a live webcast on their Investor Relations page.

Positive

• Ongoing clinical trials for X-linked retinitis pigmentosa and achromatopsia.
• Strategic partnerships with Otonomy and Bionic Sight.

Negative

• None.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2021 after the market closes on Monday, May 17, 2021. AGTC management will host a conference call beginning at 4:30 PM Eastern Time on the same date to review results and provide a corporate update.

To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

FAQ

When will AGTC announce its financial results for Q1 2021?

AGTC will announce its financial results for the fiscal quarter ended March 31, 2021, on May 17, 2021.

What time is AGTC's conference call to discuss financial results?

The conference call to discuss AGTC's financial results will begin at 4:30 PM Eastern Time on May 17, 2021.

What therapies is AGTC currently developing?

AGTC is developing gene therapies for rare retinal diseases, focusing on X-linked retinitis pigmentosa and achromatopsia.

How can I access AGTC's conference call?

You can access AGTC's conference call by dialing 877-407-6184 (US) or 201-389-0877 (outside US), or via a live webcast on their Investor Relations page.